Overcoming
chemotherapy
resistance

Half of all
cancer patients
fail chemotherapy

High unmet medical needs

Overcoming chemotherapy resistance

Our goal at Scandion Oncology is to develop drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is our mission.

Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy.

Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance against chemotherapy drugs. Few of these patients survive.

Read more about us

Stay updated with our newsletter

Get notified on mail, when news or press release is posted on our website.

First-in-class cancer treatment

Scandion Oncology will provide new cancer treatments to help overcome chemotherapy resistance for thousands of patients.

Detailed analyses estimate the market to be more than EUR 4 billion annually.

Fast and low-cost track to results

We aim to conclude one Phase II trial within the next two years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Forceful and attractive patents

Scandion Oncology has a forceful patent portfolio lasting until 2037. The patents could be attractive for big pharma to combine with existing cancer treatments.

Pipeline

Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning one Phase II trial within metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.

Investors

Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.